- Case report
- Open Access
- Open Peer Review
Early bronchopulmonary involvement in Crohn disease: a case report
© Valletta et al; licensee BioMed Central Ltd. 2001
- Received: 6 September 2001
- Accepted: 6 November 2001
- Published: 6 November 2001
Bronchopulmonary manifestations of Crohn disease have been rarely described in children, including both subclinical pulmonary involvement and severe lung disease.
A 6.5-year-old girl is described with early recurrent bronchopulmonary symptoms both at presentation and in the quiescent phase of Crohn disease. Pulmonary function tests (lung volumes and flows, bronchial reactivity and carbon monoxide diffusing capacity) were normal. Bronchoalveolar cytology showed increased (30%) lymphocyte counts and bronchial biopsy revealed thickening of basal membrane and active chronic inflammation.
Clinical and histological findings in our young patient suggest involvement of both distal and central airways in an early phase of lung disease. The pathogenesis of Crohn disease-associated lung disorders is discussed with reference to the available literature. A low threshold for pulmonary evaluation seems to be advisable in all children with CD.
- Crohn Disease
- Bronchiolitis Obliterans
- Bronchial Biopsy
- Angiotensin Converting Enzyme Activity
- Allergic Bronchopulmonary Aspergillosis
Bronchopulmonary manifestations of Crohn disease (CD) in children have been rarely described up to now. As it was already observed in adults [1–3], latent pulmonary involvement is likely to occur also in children with CD [4, 5] but few cases of severe lung disease have been reported in the pediatric age [6–10]. We describe a girl who presented early recurrent bronchopulmonary symptoms both at presentation and in the quiescent phase of CD.
A 6.5-year-old Caucasian girl, was admitted reporting a 6-month history of recurrent, bilateral hip arthralgia and recent appearance of abdominal pain and non-bloody diarrhoea, fever and weight loss. Lung examination suggested left lower lobe bronchopneumonia that was confirmed by chest x-ray. Weight and height were 24 kg (+1 SD) and 123 cm (+1 SD) respectively. Erythrocyte sedimentation rate (ESR) was 43 mm/h, C-reactive protein (CRP) 190 mg/L and haemoglobin concentration 83 g/L. Mantoux testing (1/1000) was negative and serum immunoglobulins and angiotensin converting enzyme activity were in the normal range. She was HLA-B27 positive. Sonographic examination of hips and knees showed bilateral, clear joint effusion. Esophagogastroduodenoscopy was normal and duodenal mucosa biopsies showed signs of active chronic inflammation. At colonoscopy, descending and sigmoid colon and rectum had inflamed and easily bleeding mucosa. lleum and ascending colon were normal. Mucosal biopsy specimens showed extended chronic inflammation with non-caseating epithelioid granulomas in distal colon consistent with the diagnosis of Crohn colitis. The initial treatment consisted of semielemental diet, 1 mg/kg oral prednisone daily, 1 g sulphasalazine daily, oral metronidazole and intravenous ampicillin. Clinical remission of both CD and arthritis was rapidly obtained and pulmonary symptoms and radiological abnormalities resolved. Prednisone was discontinued after three months and sulphasalazine was switched to 1.2 g mesalazine daily after two months. No relapse of CD has been observed since then.
Lymphocyte typing in blood and in bronchoalveolar lavage.
Pulmonary function evaluation, performed when the girl was asymptomatic, was unremarkable. Lung volumes were measured in a constant-volume whole-body plethysmograph, showing normal total lung capacity (98% of the predicted value), functional residual capacity (101% predicted) and residual volume (76% predicted). Spirometry was measured by means of a 12-L bell spirometer (Collins) revealing a normal shaped flow-volume curve, as well as normal forced expiratory volume in 1 sec. (FEV1, 115% predicted), forced vital capacity (FVC, 112% predicted) and FEV1/FVC (89% predicted). No change was observed after the inhalation of salbutamol 200 mcg. Bronchial hyperreactivity (BHR) was tested and ruled out by a methacholine provocation test. The diffusing capacity was also normal with a transfer factor for carbon monoxide (TLCO) of 103% predicted.
CD should be regarded as a multisystem disorder that involves mainly the gastrointestinal tract. Although the overall prevalence of concomitant bronchopulmonary manifestations has been evaluated as low as 0.4% , subclinical involvement in at least half of adults with CD has been demonstrated by some authors [1, 3, 12, 13] suggesting underlying bronchial inflammation. In children with CD, pulmonary abnormalities have been anecdotally reported, including non-caseating epithelioid granulomas [6, 7, 9, 10], bronchiolitis obliterans , desquamative interstitial pneumonitis  and bronchopulmonary suppuration , as well as respiratory function abnormalities in asymptomatic children [4, 5].
The clinical features of bronchopulmonary involvement in our patient seem to be interesting for several reasons. The first is that respiratory symptoms appeared in a young girl concurrently with the early manifestations of intestinal disease. Lung abnormalities were not directly related to the degree of activity of intestinal disease, as suggested by the second colonoscopy that confirmed histological remission of CD. If we make the hypothesis that in CD a common antigenic stimulus may activate the local immune system both in the gut and the lung , we might argue that the reactivity of each organ is likely to develop in a partially independent way. Early involvement of the lung in children with CD was also observed by Munck et al.  who showed in patients at diagnosis a significant impairment of TLCO suggesting an interstitial pulmonary process.
The results of bronchoalveolar cytology and of bronchial biopsy are consistent with involvement of both distal and central airways. The increased percentage of lymphocytes observed in BAL indicates a lymphocyte alveolitis resembling that already observed in adults with CD or other granulomatous diseases  and in the child described by Minic et al. . Thickening of bronchial basal membrane in the absence of granulomatous lesions is an unusual finding in children with CD-associated lung disease. Similar histopathological findings, due to increased subepithelial collagen deposition beneath the basal membrane, have been reported in other chronic respiratory disorders with a strong inflammatory component, such as asthma, chronic bronchitis and tuberculosis . Unfortunately, biopsy specimens were very scarce and we cannot exclude that the evidence of granulomas may have been missed.
Lung abnormalities observed in our patient were unrelated to pharmacological treatment. Respiratory involvement was concurrent with the diagnosis of CD and recurred after three months from sulphasalazine withdrawal. Neither peripheral eosinophilia nor eosinophilia in the BAL – typical signs of mesalamine-induced lung disease  – were observed and mesalamine had not to be withdrawn.
Respiratory function tests were normal. In particular, there was no evidence of BHR or reduced carbon monoxide diffusing capacity. BHR was recently observed in 71% of 14 children with CD  and in 45% of 38 adults with CD or ulcerative colitis  and did not seem to be influenced neither by activity nor by treatment or duration of CD. The pathogenesis of BHR in CD is still unknown but it may be a consequence of subclinical bronchial inflammation, induced by the bronchial homing of lymphocytes activated in the intestinal mucosa. Impairment of TLCO, suggesting an interstitial pulmonary process, has been reported in 19/20 children during active CD and in 5/10 during remission . The apparent discrepancy, between histological and cytological abnormalities and the absence of functional anomalies in our patient, may be due to the still unexplained variability of these phenomena in CD, or to the early phase of lung disease in which studies were performed.
There is increasing evidence that CD-associated respiratory disease represents a problem also in the pediatric age. Although it is not yet clear if these patients represent a subset of CD population and if they need a different therapeutic approach, a low threshold for pulmonary evaluation is advisable in all children with CD.
- Bonniere P, Wallaert B, Cortot A, Marchandise X, Riou Y, Tonnel AB, Colombel JF, Voisin C, Paris JC: Latent pulmonary involvement in Crohn's disease: biological, functional, bronchoalveolar lavage and scintigraphic studies. Gut. 1986, 27: 919-925.View ArticlePubMedPubMed CentralGoogle Scholar
- Eade OE, Smith CL, Alexander JR, Whorwell PJ: Pulmonary function in patients with inflammatory bowel disease. Am J Gastroenterol. 1980, 3: 154-156.Google Scholar
- Louis E, Louis R, Drion V, Bonnet V, Lamproye A, Radermecker M, Belaiche J: Increased frequency of bronchial hyperresponsiveness in patients with inflammatory bowel disease. Allergy. 1995, 50: 729-733.View ArticlePubMedGoogle Scholar
- Mansi A, Cucchiara S, Greco L, Sarnelli P, Pisanti C, Franco MT, Santamaria F: Bronchial hyperresponsiveness in children and adolescents with Crohn's disease. Am J Respir Crit Care Med. 2000, 161: 1051-1054.View ArticlePubMedGoogle Scholar
- Munck A, Murciano D, Pariente R, Cezard JP, Navarro J: Latent pulmonary function abnormalities in children with Crohn's disease. Eur Respir J. 1995, 8: 377-380. 10.1183/09031936.95.08030377.View ArticlePubMedGoogle Scholar
- Bentur L, Lachter J, Koren I, Ben-lzhak O, Lavy A, Bentur Y, Rosenthal E: Severe pulmonary disease in association with Crohn's disease in a 13-year-old girl. Pediatr Pulmonol. 2000, 29: 151-154. 10.1002/(SICI)1099-0496(200002)29:2<151::AID-PPUL10>3.0.CO;2-W.View ArticlePubMedGoogle Scholar
- Calder CJ, Lacy D, Raafat F, Weller PH, Booth IW: Crohn's disease with pulmonary involvement in a 3 year old boy. Gut. 1993, 34: 1636-1638.View ArticlePubMedPubMed CentralGoogle Scholar
- Henrion F, Bretagne MC, Neimann L, Flechon PE, Canton Ph, Hoeffel JC: Association exceptionelle de lésions pulmonaires, cutanée et d'une iléite terminale chez un enfant de 11 ans. J Radiol. 1982, 63: 123-126.PubMedGoogle Scholar
- Minic P, Perisic VN, Minic A: Metastatic Crohn's disease of the lung. J Pediatr Gastroenterol Nutr. 1998, 27: 338-341. 10.1097/00005176-199809000-00013.View ArticlePubMedGoogle Scholar
- Puntis JWL, Tarlow MJ, Raafat F, Booth IW: Crohn's disease of the lung. Arch Dis Child. 1990, 65: 1270-1271.View ArticlePubMedPubMed CentralGoogle Scholar
- Rodgers BH, dark LM, Kirsner YB: The epidemiologic and demographic characteristics of inflammatory bowel disease: an analysis of a computerized file of 1,400 patients. J Crohn Dis. 1971, 24: 743-753.Google Scholar
- Fireman Z, Osipov A, Kivity S, Kopelman Y, Sternberg A, Lazarov E, Fireman E: The use of induced sputum in the assessment of pulmonary involvement in Crohn's disease. Am J Gastroenterol. 2000, 95: 730-734. 10.1016/S0002-9270(99)00902-8.View ArticlePubMedGoogle Scholar
- Kuzela L, Vavrecka A, Prikazska M, et al: Pulmonary complications in patients with inflammatory bowel disease. Hepatogastroenterol. 1999, 46: 1714-1719.Google Scholar
- Teague WG, Sutphen JL, Fechner RE: Desquamative interstitial pneumonitis complicating inflammatory bowel disease of childhood. J Pediatr Gastroenterol Nutr. 1985, 4: 663-667.View ArticlePubMedGoogle Scholar
- Djukanovic R, Roche WR, Wilson JW, Beasley CRW, Twentyman OT, Howarth PH, Holgate ST: Mucosal inflammation in asthma. Am Rev Respir Dis. 1990, 142: 434-457.View ArticlePubMedGoogle Scholar
- Bitton A, Peppercorn MA, Hanrahan JP, Upton MP: Mesalamine-induced lung toxicity. Am J Gastroenterol. 1996, 91: 1039-1040.PubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-230X/1/13/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.